Cargando…

Indirect Costs of Inflammatory Bowel Diseases: A Comparison of Patient-Reported Outcomes Across 12 European Countries

BACKGROUND: National studies report a high variability of indirect costs of inflammatory bowel disease (IBD). In this study, selected aspects of the societal burden of IBDs were compared between 12 European countries. METHODS: A questionnaire-based study among adult patients with IBD was performed....

Descripción completa

Detalles Bibliográficos
Autores principales:	Holko, Przemysław, Kawalec, Paweł, Sajak-Szczerba, Magdalena, Avedano, Luisa, Mossakowska, Małgorzata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152296/ https://www.ncbi.nlm.nih.gov/pubmed/35792501 http://dx.doi.org/10.1093/ibd/izac144

Ejemplares similares

Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries
por: Holko, Przemysław, et al.
Publicado: (2022)

Health-Related Quality of Life Impairment and Indirect Cost of Crohn’s Disease: A Self-Report Study in Poland
por: Holko, Przemysław, et al.
Publicado: (2016)

Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2017)

Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR(®) TS
por: Holko, Przemyslaw, et al.
Publicado: (2011)

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018)

Cost-utility analysis of Ruconest(®) (conestat alfa) compared to Berinert(®) P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema
por: Kawalec, Paweł, et al.
Publicado: (2013)

Indirect costs of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. A systematic review
por: Kawalec, Paweł
Publicado: (2016)

A Comment on Craig et al.: ‘‘Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization: A NICE Single Technology Appraisal’’
por: Holko, Przemysław, et al.
Publicado: (2013)

Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2018)

Impact of Biologic Treatment of Crohn’s Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland
por: Holko, Przemysław, et al.
Publicado: (2018)

What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study
por: Schoefs, Elise, et al.
Publicado: (2022)

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2012)

Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis
por: Krawczyk, Kinga, et al.
Publicado: (2023)

Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2016)

Disease activity, quality of life and indirect costs of reduced productivity at work, generated by Polish patients with ankylosing spondylitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations
por: Le Berre, Catherine, et al.
Publicado: (2020)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Indirect Costs Due to Lung Cancer-Related Premature Mortality in Four European Countries
por: Bencina, Goran, et al.
Publicado: (2023)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Conjugal inflammatory bowel disease: a systematic review and European survey
por: Costa-Santos, Maria Pia, et al.
Publicado: (2021)

Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies
por: Armuzzi, Alessandro, et al.
Publicado: (2019)

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
por: Kawalec, P., et al.
Publicado: (2017)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Comment on: “Forecasting Pharmaceutical Prices for Economic Evaluations When There is No Market: A Review”
por: Holko, Przemysław
Publicado: (2017)

A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis
por: Stawowczyk, Ewa, et al.
Publicado: (2017)

The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care
por: Kuenzig, M Ellen, et al.
Publicado: (2019)

Cost-effectiveness of biological treatment of ulcerative colitis – a systematic review
por: Stawowczyk, Ewa, et al.
Publicado: (2017)

Relationship between physician-based assessment of disease activity, quality of life, and costs of ulcerative colitis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2018)

Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review
por: Kawalec, Paweł, et al.
Publicado: (2017)

Reimbursed medication adherence enhancing interventions in 12 european countries: Current state of the art and future challenges
por: Kardas, Przemysław, et al.
Publicado: (2022)

The relationship between inflammatory bowel disease and Helicobacter pylori across East Asian, European and Mediterranean countries: a meta-analysis
por: Imawana, Rabbiaatul Addawiyah, et al.
Publicado: (2020)

Implications of Public Interest in Colonoscopy: Analysis of Google Trends Data From 12 European Countries
por: Skrzypczak, Tomasz, et al.
Publicado: (2023)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Microcosting study of ICU costs in three European countries
por: Tan, SS, et al.
Publicado: (2008)

European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
por: Kawalec, Paweł, et al.
Publicado: (2017)

Costs in inflammatory bowel diseases
por: Petryszyn, Paweł W., et al.
Publicado: (2016)

Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study
por: Puzianowska-Kuźnicka, Monika, et al.
Publicado: (2016)

The assessment of work endurance in disability evaluations across European countries
por: Boersema, Henk-Jan, et al.
Publicado: (2018)

Epidemiological analysis of peripartum hysterectomy across nine European countries
por: Kallianidis, Athanasios F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6jfetbe4l9gf14ca3qnj2beaa1